Precursor T-Cell Acute Lymphoblastic Leukemia
Watchlist
Retrieved
2021-01-23
Source
Trials
—
Genes
PHF6,
CNOT3,
TAL1,
TLX1,
NOTCH1,
FBXW7,
ABL1,
MYB,
LMO1,
IL7R,
RPL10,
RPL5,
BAX,
BCL10,
LMO2,
BCL2,
TLX3,
BCL11B,
NUP214,
CDKN2A,
MYC,
STIL,
BCR,
SET,
MLLT10,
FLT3,
TRG,
TRD,
PTPN2,
PICALM
PHF6,
CNOT3,
TAL1,
TLX1,
NOTCH1,
FBXW7,
ABL1,
MYB,
LMO1,
IL7R,
RPL10,
RPL5,
BAX,
BCL10,
LMO2,
BCL2,
TLX3,
BCL11B,
NUP214,
CDKN2A,
MYC,
STIL,
BCR,
SET,
MLLT10,
FLT3,
TRG,
TRD,
PTPN2,
PICALM,
JAK3,
MTOR,
PTPRC,
CCND3,
TRB,
STAT5B,
DNM2,
TYK2,
TRA,
SPI1,
STAT1,
MYCN,
KDM6A,
ZFP36L2,
ABCG2,
TCL1A,
CTCF,
ZBTB16,
DDX3X,
SMARCA4,
SALL2,
ECT2L,
HNRNPH1,
PTEN,
PIK3CA,
AKT1,
PIK3CB,
TMEM132D,
PIK3CG,
PIK3CD,
KRT7,
PMEL,
HOXA@,
CD38,
NOTCH3,
DLL1,
PSMB6,
SCLY,
RUNX1,
TRBV20OR9-2,
LYL1,
TP53,
IL7,
KMT2A,
ETV6,
YY1,
CDKN2B,
NUP98,
CXCR4,
CD34,
MTAP,
ATM,
HES1,
NKX2-5,
MEF2C,
PDLIM5,
IKZF1,
H3P10,
OPN1SW,
TNFSF10,
LINC02605,
MIR223,
IL2,
KLF4,
SNAP91,
CALM3,
CALM2,
NR3C1,
CALM1,
TAL2,
RAP1GDS1,
TNF,
CD47,
ABCB1,
MME,
CDK4,
JAK1,
JAK2,
TARP,
WT1,
GLIS2,
LCK,
MBD2,
TRGC1,
CRLF2,
CDKN1A,
PDIK1L,
TRDC,
DNMT3A,
TRDD3,
SAI1,
IL2RG,
CYLD,
TRDJ1,
CD44,
MTTP,
IGF1R,
S100A4,
HMGA1,
IRAK1,
FOXM1,
MSX1,
HIF1A,
NRAS,
CD46,
MCL1,
FOXO3,
CTNNB1,
FHIT,
CCR9,
CCR7,
RASGRP1,
SOS1,
CDKN1B,
STAT5A,
MIR21,
CD79A,
CD33,
CD19,
CD7,
CD1A,
TERT,
NR2E1,
ADD3,
TNFRSF10B,
ASPG,
SOAT1,
KIT,
MAP2K7,
EZH2,
KDM6B,
USP9X,
TAF1,
PAX5,
NT5C2,
HNF1A,
TCF7,
SUZ12,
TCOF1,
PIM1,
KDM1A,
TFRC,
PAWR,
VAV1,
F2RL3,
USP7,
ALDH1A2,
RTEL1,
MLRL,
FOXP3,
MALT1,
SUB1,
PRKCQ,
RAG2,
MAP3K20,
MRPL28,
PTK7,
OLIG2,
NEUROD1,
CXCL12,
PDCD4,
ST6GAL1,
SKP2,
IKZF3,
TBC1D9,
MAPK8,
STAT3,
MSH2,
MPO,
NXT1,
MAPK1,
MMP1,
CILK1,
KRAS,
DLL4,
FANCD2,
MIR146B,
PLEKHG2,
HOXA10,
HOXA9,
BAALC,
ASRGL1,
XRCC6,
CASP3,
MIR196B,
NRARP,
ARID5B,
CCND2,
FANCB,
CD22,
BMI1,
ETS1,
ERG,
CDK2,
CDK6,
EGFR,
ATN1,
MIR19B1,
MIR150,
TIMM8A,
TET2,
CCR4,
CSF2,
COX8A,
HSF1,
PWAR4,
BCL6,
H3P9,
CCND1,
IGFBP7,
XIAP,
THAP1,
IFNG,
IGF1,
IGH,
DEL11P13,
LDB1,
ABCC5,
MIR181A1,
EDIL3,
MIR2909,
KLRC4-KLRK1,
SMC4,
MIR204,
DNM1L,
PROM1,
MIR200B,
MIR26B,
PTPRU,
MIR663B,
NRP2,
MYB-AS1,
MIR141,
SNHG5,
H3P5,
MIR106A,
TRIM13,
MIR139,
DHRS9,
GATD3B,
MIR142,
MIR20A,
MIR146A,
EBI3,
NALT1,
IL18R1,
FEM1B,
MIR17,
MIR29A,
ALL1,
MIR29B1,
NR1I3,
MIR576,
NUP155,
MIR451A,
MIR452,
MIR485,
TCL1B,
PTGES,
GDF15,
ATG5,
MED12,
CLDN10,
MIR193B,
GRAP2,
COX5A,
LHX2,
ARHGEF2,
CXADRP1,
SOCS5,
HDAC4,
TOX,
MIR20B,
MAGI1,
MAFB,
MIR29B2,
MIR30A,
MIR1290,
MIR664A,
MIR17HG,
MIR708,
ZFAS1,
MIR590,
SLC7A7,
LNCR1,
MIR363,
ZEB2,
MSLN,
MAML1,
AHSA1,
TRIM59,
TRBV16,
TRAV29DV5,
ZMIZ1,
CNOT6,
TRBC1,
STIM2,
POLD4,
PRDM16,
PRDM14,
TRBV7-9,
DEPTOR,
TMEM102,
FRTS1,
IGHJ2,
IRX3,
BBC3,
MUL1,
EFL1,
LATS2,
NANOG,
GNL3,
TRAJ60,
TRAC,
CD274,
RMC1,
DENR,
BCOR,
PINX1,
MSTO1,
SHQ1,
WWOX,
ASB2,
ATF7IP,
CCAR1,
LEF1,
DIABLO,
APIP,
POLE4,
SLC2A4RG,
NMD3,
POGLUT1,
SLC12A9,
A1CF,
AVEN,
SCD5,
POLDIP2,
AUTS2,
HENMT1,
RASGRP4,
JDP2,
RASSF1,
CTCFL,
CNKSR3,
CBLL2,
NKX2-3,
TNFSF13B,
UBR1,
PRSS55,
KHDRBS1,
CERS6,
GNLY,
CCT4,
FAM133B,
ASPM,
ATG7,
MERTK,
RACK1,
WIF1,
DNER,
SETBP1,
LRSAM1,
CCDC28A,
RNF19A,
PANX1,
DAPK2,
TET1,
VMP1,
ROPN1L,
TCHP,
CARD11,
MAML2,
HEY2,
BRD4,
SIRT1,
DICER1,
USP24,
SPZ1,
ORAI1,
KLRK1,
MCU,
AKR1C3,
ABCA2,
LMO4,
GATA1,
FUT1,
FRAXE,
FOSB,
FOS,
AFF2,
FGFR1,
FCGRT,
FCER2,
EWSR1,
MECOM,
ETV5,
ETS2,
EPHB6,
EPHB2,
EML1,
EIF4A2,
EIF4A1,
DUSP1,
DTX1,
DNTT,
DNMT3B,
DNMT1,
DNASE1L3,
DHFR,
AKR1C1,
GABPA,
GATA3,
MAPK14,
GFER,
IL18,
IL17A,
IL16,
IL10,
CXCL8,
IL4,
IL3RA,
IL2RB,
IL1B,
RBPJ,
IGHM,
IARS1,
HTC2,
HSP90AA1,
HSD17B1,
HRAS,
HPRT1,
HOXD@,
HOXA13,
HOXA11,
HOXA7,
HNMT,
HHEX,
GRIA1,
GPER1,
CXADR,
CRYZ,
ITGAM,
RUNX2,
CALR,
CALCR,
CA12,
C3,
BTG1,
ZFP36L1,
BRCA2,
BRAF,
BRCA1,
BCL2L1,
NKX3-2,
AVPR2,
ASPA,
ASIP,
ARSA,
ARRB1,
ARR3,
FAS,
APRT,
APAF1,
JAG1,
PARP1,
ADD1,
ACTB,
ABL2,
CASR,
CBFB,
CRMP1,
CCK,
CRK,
CREM,
CREBBP,
ATF2,
CPOX,
COL4A5,
CCR6,
CLTC,
CKS2,
CKS1B,
CHRNA4,
CHRM3,
CHKA,
CHEK1,
CFTR,
CDKN2C,
CDC25A,
CD59,
CD6,
CD5,
CD247,
CD3E,
CD3D,
CD2,
CCNC,
INPP5D,
JUN,
IRS4,
TFAP2C,
ZEB1,
TCF3,
TAPBP,
TALDO1,
MAP3K7,
STIM1,
SRC,
SPG7,
SOX4,
SLC9A1,
SLC6A8,
SLC1A2,
SIAH2,
SEMA3F,
ABCA3,
S100A8,
RPS15,
RPS6KA3,
RPL22,
RPL15,
ROS1,
RHO,
REG1A,
RBBP8,
RASGRF1,
TF,
TGM2,
RASA1,
THBS1,
FOXN1,
NR0B2,
GATD3A,
TAM,
CDR3,
SLC7A5,
HMGA2,
AIMP2,
DEK,
ZFX,
ZFP36,
WNT11,
TRPV1,
UTRN,
UFD1,
UCN,
U2AF1,
TYMS,
TSC2,
TSN,
TRAF5,
CRISP2,
TPD52,
TLE1,
NKX2-1,
RASA2,
RAF1,
JUNB,
NHLH1,
NFE2L2,
NFATC3,
NF1,
NCAM1,
NBN,
NAP1L1,
MSX2,
ABCC1,
MPST,
MMP9,
MMP2,
AFDN,
MLLT1,
MAP3K10,
CD99,
MFAP1,
MEIS1,
MCM2,
MATK,
SMAD3,
LTBR,
LTB,
AFF3,
CD82,
JUND,
NFKBIE,
NKX3-1,
RAC1,
NOTCH2,
PTPN11,
PTPN6,
PTPN1,
PSEN1,
PRL,
PRKCA,
PRKAR1A,
PRKAB1,
PRKAA2,
PRKAA1,
PTPA,
PMAIP1,
PLP2,
PLK1,
PITX1,
PIN1,
SLC25A3,
PDGFRA,
PDCD1,
PCNA,
PBX2,
PAX6,
PRKN,
SIX6,
YBX1,
CCL25
Drugs
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) amino)methyl)tetrahydrofuran-3,4-diol,
6-thioguanine (oral liquid),
Allogeneic CD34+ cells expanded ex vivo with an aryl hydrocarbon receptor antagonist
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) amino)methyl)tetrahydrofuran-3,4-diol,
6-thioguanine (oral liquid),
Allogeneic CD34+ cells expanded ex vivo with an aryl hydrocarbon receptor antagonist,
Allogeneic T cells encoding an exogenous TK gene,
Allogeneic ex vivo expanded umbilical cord blood cells,
Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus,
Allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2,
Aplidine,
Autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor),
Autologous engineered anti -CD19 Chimeric Antigen Receptor (CAR +) T -cells
(
KYMRIAH
),
Axicabtagene ciloleucel
(
YESCARTA
),
Blinatumomab
(
BLINCYTO
),
Clofarabine
(
CLOLAR,
EVOLTRA,
IVOZALL
),
Crisantaspase,
Dasatinib
(
SPRYCEL
),
Epratuzumab,
Eryaspase
(
GRASPA
),
Forodesine hydrochloride,
Hematopoietic stem and progenitor cells expanded ex-vivo with a low molecular weight aryl hydrocarbon receptor (AHR) antagonist,
Imatinib mesilate
(
GLEEVEC,
GLIVEC,
IMATINIB TEVA,
IMATINIB TEVA B.V.
),
Iodine (131I) tositumomab,
L-Asparaginase
(
KIDROLASE,
SPECTRILA
),
Mercaptopurine (oral liquid),
Mercaptopurine (oral suspension)
(
PURIXAN,
XALUPRINE
),
Methotrexate (oral liquid)
(
JYLAMVO
),
Nelarabine
(
ARRANON,
ATRIANCE
),
Pegaspargase
(
ONCASPAR,
PEGASPAR
),
Pegylated L-asparaginase,
Pegylated recombinant Erwinia chrysanthemi L-asparaginase,
Plitidepsin,
Ponatinib
(
ICLUSIG
),
Recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3,
Siplizumab,
Stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells,
Vincristine sulfate liposomes
(
MARQIBO
),
haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate
Registered!
A rare acute lymphoblastic leukemia characterized by a neoplasm of lymphoblasts committed to the T-cell lineage, involving bone marrow and blood. A value of >25% bone marrow blasts may be used to define leukemia (as opposed to lymphoma) in cases with the presence of a mass lesion in addition to bone marrow involvement. Patients typically present with leukocytosis, and frequently with a large mediastinal or other tissue mass. Lymphadenopathy and hepatosplenomegaly are common.